{"id":48497,"date":"2022-09-16T16:01:54","date_gmt":"2022-09-16T14:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/"},"modified":"2022-09-16T16:01:54","modified_gmt":"2022-09-16T14:01:54","slug":"feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/","title":{"rendered":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug"},"content":{"rendered":"
\n

\nData published in the New England Journal of Medicine reports litifilimab may help <\/i>those diagnosed with <\/i>systemic lupus erythematosus<\/i>\n<\/p>\n

MANHASSET, N.Y.–(BUSINESS WIRE)–Northwell Health\u2019s Division of Rheumatology and The Feinstein Institutes for Medical Research<\/a> recently published in the New England Journal of Medicine <\/i>(NEJM)<\/a> data showing that an experimental lupus therapy reduced disease activity in joints of patients and globally improved their condition. The Biogen Inc.-sponsored phase 2 LILAC (Part A) clinical trial evaluated the efficacy of the investigational monoclonal antibody drug litifilimab (BIIB059) to treat systemic lupus erythematosus (SLE).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe trial, which was randomized, double-blind, placebo-controlled and led by Richard Furie, MD<\/a>, chief of the Division of Rheumatology at Northwell, evaluated the efficacy and safety of litifilimab in two parts. Part B, which was published<\/a> in NEJM<\/i> in July 2022, looked at litifilimab\u2019s effects on those with cutaneous lupus erythematosus (CLE). Part A\u2019s results published September 8.\n<\/p>\n

\n\u201cPatients live with SLE their entire lives and experience chronic inflammation, pain and potentially organ failure,\u201d said Dr. Furie, professor in the Institute of Molecular Medicine<\/a> at the Feinstein Institutes. \u201cThe results from this trial show that litifilimab may effectively block the body\u2019s production of harmful inflammatory molecules in people with SLE, easing their joint pain and improving overall disease activity.\u201d\n<\/p>\n

\nIn patients with SLE, the immune system attacks the body\u2019s tissues, causing widespread inflammation and damage to the affected organs. SLE impacts the joints, skin, brain, lungs, kidneys and blood vessels. There is no cure for lupus, but it can be treated with medical interventions. This second manuscript published in NEJM helps give a bigger picture to the potential litifilimab therapy holds for people with both systemic and cutaneous lupus.\n<\/p>\n

\n\u201cInflammation is the hallmark of lupus,\u201d said Kevin J. Tracey, MD,<\/a> president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. \u201cUnder Dr. Furie\u2019s leadership, this clinical trial may lead to a new and much-needed option for combatting inflammatory cytokines that worsen the disease.\u201d\n<\/p>\n

\nOne hundred and thirty-two participants enrolled in the study were either given 450 mg of litifilimab or placebo subcutaneously every four weeks for 20 weeks, with an additional dose given at week two. Clinicians then analyzed the active joint counts in the trial\u2019s enrollees, which determined that there was a greater reduction of swollen and tender joints than the placebo over 24 weeks. Effects on global disease as well as skin activity were also evaluated. Longer and larger trials are needed, and Biogen Inc. is currently enrolling two phase 3 studies in 31 countries worldwide and plans to initiate a pivotal study in cutaneous lupus erythematosus (CLE) later this year.\n<\/p>\n

\nDr. Furie is an internationally recognized leader in lupus research. Under his guidance, Dr. Furie helped lead several clinical trials<\/a> that resulted in the Food and Drug Administration\u2019s approval of new therapies for SLE. These included Saphnelo (anifrolumab) to treat SLE and Benlysta (belimumab) for lupus nephritis, the first approved therapy to treat that form of lupus.\n<\/p>\n

\nAbout the Feinstein Institutes
\n
<\/i><\/b>The Feinstein Institutes for Medical Research<\/i><\/a> is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine \u2013 a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit<\/i> <\/i>http:\/\/feinstein.northwell.edu<\/i><\/a> <\/i>and follow us on<\/i> <\/i>LinkedIn<\/i><\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMatthew Libassi
\n
631-793-5325
\n
mlibassi@northwell.edu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Data published in the New England Journal of Medicine reports litifilimab may help those diagnosed with systemic lupus erythematosus MANHASSET, N.Y.–(BUSINESS WIRE)–Northwell Health\u2019s Division of Rheumatology and The Feinstein Institutes for Medical Research recently published in the New England Journal of Medicine (NEJM) data showing that an experimental lupus therapy reduced disease activity in joints … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48497","6":"format-standard","7":"category-industry"},"yoast_head":"\nFeinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Data published in the New England Journal of Medicine reports litifilimab may help those diagnosed with systemic lupus erythematosus MANHASSET, N.Y.–(BUSINESS WIRE)–Northwell Health\u2019s Division of Rheumatology and The Feinstein Institutes for Medical Research recently published in the New England Journal of Medicine (NEJM) data showing that an experimental lupus therapy reduced disease activity in joints ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-16T14:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug\",\"datePublished\":\"2022-09-16T14:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/\"},\"wordCount\":639,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005031\\\/en\\\/1573624\\\/21\\\/Furie_Richard_WEB_3.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/\",\"name\":\"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005031\\\/en\\\/1573624\\\/21\\\/Furie_Richard_WEB_3.jpg\",\"datePublished\":\"2022-09-16T14:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005031\\\/en\\\/1573624\\\/21\\\/Furie_Richard_WEB_3.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220916005031\\\/en\\\/1573624\\\/21\\\/Furie_Richard_WEB_3.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/","og_locale":"en_US","og_type":"article","og_title":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend","og_description":"Data published in the New England Journal of Medicine reports litifilimab may help those diagnosed with systemic lupus erythematosus MANHASSET, N.Y.–(BUSINESS WIRE)–Northwell Health\u2019s Division of Rheumatology and The Feinstein Institutes for Medical Research recently published in the New England Journal of Medicine (NEJM) data showing that an experimental lupus therapy reduced disease activity in joints ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-16T14:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug","datePublished":"2022-09-16T14:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/"},"wordCount":639,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/","url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/","name":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg","datePublished":"2022-09-16T14:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220916005031\/en\/1573624\/21\/Furie_Richard_WEB_3.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-led-lupus-phase-2-clinical-trial-shows-promise-of-an-investigational-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48497"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48497\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}